Malaysian Genomics Resource Centre Berhad Balance Sheet Health

Financial Health criteria checks 4/6

Malaysian Genomics Resource Centre Berhad has a total shareholder equity of MYR22.1M and total debt of MYR0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are MYR25.7M and MYR3.6M respectively.

Key information

Debt to equity ratio

RM0

Debt

Interest coverage ratio	n/a
Cash	RM7.36m
Equity	RM22.09m
Total liabilities	RM3.62m
Total assets	RM25.70m

Recent financial health updates

We Think Malaysian Genomics Resource Centre Berhad (KLSE:MGRC) Can Afford To Drive Business Growth

Feb 15

Companies Like Malaysian Genomics Resource Centre Berhad (KLSE:MGRC) Are In A Position To Invest In Growth

Nov 02

Recent updates

Is Now An Opportune Moment To Examine Malaysian Genomics Resource Centre Berhad (KLSE:MGRC)?

Mar 02

We Think Malaysian Genomics Resource Centre Berhad (KLSE:MGRC) Can Afford To Drive Business Growth

Feb 15

Companies Like Malaysian Genomics Resource Centre Berhad (KLSE:MGRC) Are In A Position To Invest In Growth

Nov 02

Financial Position Analysis

Short Term Liabilities: MGRC's short term assets (MYR16.1M) exceed its short term liabilities (MYR2.0M).

Long Term Liabilities: MGRC's short term assets (MYR16.1M) exceed its long term liabilities (MYR1.6M).

Debt to Equity History and Analysis

Debt Level: MGRC is debt free.

Reducing Debt: MGRC has no debt compared to 5 years ago when its debt to equity ratio was 103.2%.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if MGRC has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if MGRC has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.

Malaysian Genomics Resource Centre Berhad Balance Sheet Health

Financial Health criteria checks 4/6

Key information

Recent financial health updates

We Think Malaysian Genomics Resource Centre Berhad (KLSE:MGRC) Can Afford To Drive Business Growth

Companies Like Malaysian Genomics Resource Centre Berhad (KLSE:MGRC) Are In A Position To Invest In Growth

Recent updates

New major risk - Revenue and earnings growth

Malaysian Genomics Resource Centre Berhad, Annual General Meeting, Apr 29, 2024

Malaysian Genomics Resource Centre Berhad, Annual General Meeting, Apr 29, 2024

Malaysian Genomics Resource Centre Berhad Announces Redesignation of Encik Muhammad Badri Bin Hussin to Chief Operating Officer from Director

Full year 2023 earnings: EPS and revenues miss analyst expectations

Malaysian Genomics Resource Centre Berhad Announces Update on Material Litigation

Malaysian Genomics Resource Centre Berhad Appoints Mohammad Hasni Bin Ibrahim as Independent and Non Executive Director

Malaysian Genomics Resource Centre Berhad Appoints Datuk Wira Muhammad Faizal Bin Zainol as Independent and Non Executive Director

Malaysian Genomics Resource Centre Berhad Announces Re-Designation of Aswath A/L Ramakrishnan as A Non-Audit and Risk Management Committee Member

Malaysian Genomics Resource Centre Berhad Provides Material Litigation Update

Malaysian Genomics Resource Centre Berhad Appoints Encik Muhammad Badri Bin Hussin, Age 50, as Member of Audit Committee, Date of Change 25 Oct 2023

Malaysian Genomics Resource Centre Berhad Announces Appointment of Encik Muhammad Badri Bin Hussin as Independent and Non Executive Director

Malaysian Genomics Resource Centre Berhad Announces Appointment of Encik Mohamad Ruzaini Bin Hamzah as Independent and Non Executive Director

Malaysian Genomics Resource Centre Berhad Announces Resignation of Encik Sasha Omar Firdaus Bin Aamir Nordin as Chief Executive Officer

Full year 2023 earnings released: RM0.11 loss per share (vs RM0.059 profit in FY 2022)

Malaysian Genomics Resource Centre Berhad Announces Resignation of Aswath A/L Ramakrishnan as Independent and Non Executive Member of Nomination and Remuneration Committee

High number of new and inexperienced directors

Malaysian Genomics Resource Centre Berhad Appoints Miss Chih Yi May as Independent and Non Executive Director effective June 1, 2023

High number of new and inexperienced directors

Consensus revenue estimates fall by 33%

Malaysian Genomics Resource Centre Berhad Appoints Encik Syed Zulkifli Bin Syed Ismail as Independent and Non Executive Member of Nomination and Remuneration Committee

Third quarter 2023 earnings released: RM0.022 loss per share (vs RM0.016 profit in 3Q 2022)

Malaysian Genomics Resource Centre Berhad Re-designates Encik Mohd Shakir Bin Shahimi to Chairman of Audit Committee

Malaysian Genomics Resource Centre Berhad Appoints Mr. Aswath A/L Ramakrishnan as Independent and Non Executive Director

Is Now An Opportune Moment To Examine Malaysian Genomics Resource Centre Berhad (KLSE:MGRC)?

Price target decreased by 13% to RM0.95

Second quarter 2023 earnings released: RM0.01 loss per share (vs RM0.008 profit in 2Q 2022)

First quarter 2023 earnings released: EPS: RM0.007 (vs RM0.002 in 1Q 2022)

Malaysian Genomics Resource Centre Berhad Announces the Re-Designation of Encik Mohd Shakir Bin Shahimi from Member of Nomination and Remuneration Committee to Chairman of Nomination and Remuneration Committee

High number of new and inexperienced directors

Malaysian Genomics Resource Centre Berhad Announces Resignation of Teoh Ai Ling as Principal Officer

Full year 2022 earnings released: EPS: RM0.059 (vs RM0.04 loss in FY 2021)

High number of new and inexperienced directors

Full year 2022 earnings released: EPS: RM0.059 (vs RM0.04 loss in FY 2021)

Malaysian Genomics Resource Centre Berhad Appoints Encik Mohd Shakir Bin Shahimi as Member of Nomination and Remuneration Committee

High number of new and inexperienced directors

Malaysian Genomics Resource Centre Berhad announces redesignation of Dato' Seri Dr. Chen Chaw Min from Independent Director to Independent and Non Executive Chairman

Others Malaysian Genomics Announces Board Changes

Malaysian Genomics Resource Centre Berhad Appoints Ku Chong Hong, Designation Chairman of Nomination and Remuneration Committee Directorate Independent and Non Executive, Date of Change 13 Jul 2022

Third quarter 2022 earnings released: EPS: RM0.016 (vs RM0.002 in 3Q 2021)

High number of new and inexperienced directors

Malaysian Genomics Resource Centre Berhad Announces the Launch of Its Genetic Screening Plus Personalised Health Supplements Solutions on the Airasia Super App

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Malaysian Genomics Resource Centre Berhad Announces Re-Designation of Encik Noor Azri Bin Dato' Sri Noor Azerai as Independent Executive Director

We Think Malaysian Genomics Resource Centre Berhad (KLSE:MGRC) Can Afford To Drive Business Growth

High number of new and inexperienced directors

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

High number of new directors

Financial Controller Sek Cheah has left the company

Senior Independent Non-Executive Chairman Rafiah Salim has left the company

Companies Like Malaysian Genomics Resource Centre Berhad (KLSE:MGRC) Are In A Position To Invest In Growth

Full year 2021 earnings released: RM0.04 loss per share (vs RM0.062 loss in FY 2020)

High number of new directors

New 90-day high: RM1.22

New 90-day high: RM1.18

New 90-day high: RM1.11

New 90-day high: RM0.80

Malaysian Genomics Resource Centre Berhad Renames the Audit Committee as Audit and Risk Management Committee

First quarter 2021 earnings released: RM0.008 loss per share

New 90-day high: RM0.64

Malaysian Genomics Resource Centre Berhad Announces Appointment of ENCIK SASHA OMAR FIRDAUS BIN AAMIR NORDIN as Chief Executive Officer

New 90-day high - RM0.53

Malaysian Genomics Resource Centre Berhad Announces Resignation of Encik Robert George Hercus @ Abdul Karim Hercus as Executive Managing Director

Financial Position Analysis

Debt to Equity History and Analysis

Balance Sheet

Cash Runway Analysis

Discover healthy companies